FibroGen to Present at Upcoming Investor Conferences
FibroGen, Inc. (NASDAQ: FGEN) announced that CEO Enrique Conterno will participate in two upcoming healthcare conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
FibroGen, Inc. (NASDAQ: FGEN) announced that CEO Enrique Conterno will participate in two upcoming healthcare conferences. The first is the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 4:40 PM EST, followed by the Jefferies London Healthcare Conference on November 18, 2021, at 3:00 AM EST. An audio webcast will be available on the company's Investor webpage, with replays accessible for 30 days. FibroGen focuses on developing first-in-class therapeutics, including roxadustat for anemia and pamrevlumab for various disorders.
Details
News Market Reaction – FGEN
The recorded move for FGEN in the trading session of this news was +3.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the following healthcare conferences:
- Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16 at 4:40 PM EST.
- 12th Annual Jefferies London Healthcare Conference on Thursday, November 18 at 3:00 AM EST.
An audio webcast will be available on the “Events & Presentations” section of the FibroGen Investor webpage at www.fibrogen.com. A replay will be available for approximately 30 days.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity for anemia associated with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes (MDS), and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. For more information, please visit www.fibrogen.com.
Contact:
FibroGen, Inc.
Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
mtung@fibrogen.com
Media:
Meichiel Keenan
Public Affairs
mkeenan@fibrogen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.